You are here: Industry Insights > SARS-CoV-2

News List

T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity worldpharmanews
September 18, 2020
Ever since SARS-CoV-2 first appeared, researchers have been trying to understand whether sometimes the immune system does more harm than good during the acute phase of COVID-19.
A New Test Could Identify COVID-19 Patients Who Are at Risk for Severe Illness prnewswire
September 18, 2020
A novel study in AACC's Clinical Chemistry journal shows that a new test for SARS-CoV-2 viral proteins known as antigens could determine which COVID-19 patients are most likely to become critically ill.
Designed antiviral proteins inhibit SARS-CoV-2 in the lab worldpharmanews
September 17, 2020
Computer-designed small proteins have now been shown to protect lab-grown human cells from SARS-CoV-2, the coronavirus that causes COVID-19.
Progress toward antiviral treatments for COVID-19 worldpharmanews
September 17, 2020
COVID-19 is caused by a virus known as SARS-CoV-2, which is similar in structure to two other viruses that have caused recent outbreaks: SARS-CoV, which caused an outbreak of SARS in 2003, and MERS-CoV, the cause of a 2012 outbreak of ...
Axon Announces Positive Pre-Clinical Results for Peptide Vaccine against Coronavirus americanpharmaceuticalreview
September 17, 2020
AXON Neuroscience announced positive pre-clinical results for ACvac1, its vaccine candidate against novel coronavirus SARS-CoV-2. This key pre-clinical study confirmed the efficacy of the vaccine on the live SARS CoV-2 virus.
Avacta to Launch SARS-CoV-2 ELISA Laboratory Test americanpharmaceuticalreview
September 17, 2020
Avacta, the developer of Affimer® biotherapeutics and reagents, has announced it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.
Avacta to Launch SARS-CoV-2 ELISA Lab Test contractpharma
September 17, 2020
To make a high performance Affimer research ELISA test available to support global research efforts to combat the coronavirus.
Experimental COVID-19 Drug Shows Promise in Preliminary Cell Research prnewswire
September 16, 2020
An early study in human cells found that an antiviral drug candidate, Pfizer Inc.'s PF-00835231, may be at least as potent as the drug remdesivir in blocking the reproduction of the virus that causes COVID-19.
Tiny antibody component highly effective against SARS-COV-2 in animal studies worldpharmanews
September 16, 2020
University of Pittsburgh School of Medicine scientists have isolated the smallest biological molecule to date that completely and specifically neutralizes the SARS-CoV-2 virus, which is the cause of COVID-19.
Phase I trial finds potential COVID-19 antibody treatment safe in healthy volunteers europeanpharmaceuticalreview
September 15, 2020
A first-in-human Phase I clinical trial of potential COVID-19 antibody CT-P59 has shown the treatment is well tolerated in healthy subjects.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 61 62 Next page